Our development pipeline platform, drNPC™ are directly reprogrammed neural precursor cells (drNPC), that are made from reprogramming cells that are harvested from the patient
With direct reprogramming, Regenerative Medicine is no longer be bound to use human fetal or embryonic cells (or other pluripotent sources) to derive neural cells for development of cell therapy products. This also means that a patient’s own cells can be used as the starting cells thus requiring no donors. In addition, reprogramming these neural precursor cells from the patient's own cell makes them genetically and immunologically identical to the patient, which opens many new opportunities for Regenerative Medicine and overcomes many safety hurdles.
drNPC™ are multipotent neural precursor cells that have been shown in vitro to proliferate and differentiate into neurons, astrocytes, and oligodendrocytes. drNPCs express the typical markers of neural stem cells, including Sox2, Nestin, Ascl1, Pax6, Map2 and CD133 but without pluripotency markers such as Oct4 and Nanog. Single drNPCs in vitro have been shown to form neurospheres that continue to express the neural stem cell markers, form functional gap junctions, and correctly self-organize into grey and white matter zones.
Upon transplantation in vivo, drNPC are capable of differentiating into functional neurons, astrocytes, and oligodendrocytes. In spinal cord injury models (in RNU rats), human drNPC implantation results in new myelinated axons across the injury site and functional recovery. In the 6-OHDA Parkinson’s rat model, human drNPC-A9 neurons resulted in new TH+ neurons (human-specific) and functional recovery. drNPC implantation has shown no evidence of long-term proliferation, inappropriate differentiation, or tumor formation in any of the studies.